Tumor antigen protein and use thereof
View Patent ↗An inducer of cytotoxic T cells comprising as an active ingredient a protein which comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2, or a peptide derived from the protein above is provided.
1. A method for inducing a cytotoxic T cell (CTL) comprising bringing peripheral lymphocyte cells into contact with a peptide that is 8-14 amino acids long and is:
(i) a fragment of a protein, wherein the protein consists of the amino acid sequence shown in SEQ ID NO: 2; or
(ii) a fragment of a protein, wherein the protein consists of an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2,
wherein the amino acid residue at position 2 of said fragment (ii) is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine;
wherein said peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to HLA-A24 or HLA-B55 antigen.
2. The method of claim 1 in which the peptide binds to an HLA antigen in a HLA-A24 restricted manner and is recognized by CTLs when bound to an HLA-A24 antigen.
3. The method of claim 1 , wherein the peptide is:
(i) a fragment of a protein, wherein the protein consists of the amino acid sequence shown in SEQ ID NO: 2; or
(ii) a fragment of a protein, wherein the protein consists of an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2, and the amino acid residue at position 2 of said fragment (ii) is tyrosine, phenylalanine, methionine, or tryptophan, and the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.
4. A peptide which is 8-14 amino acids long, and is:
(i) a fragment of a protein, wherein the protein consists of the amino acid sequence shown in SEQ ID NO: 2; or
(ii) a fragment of a protein, wherein the protein consists of an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2, wherein the amino acid residue at position 2 of said fragment (ii) is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine;
wherein said peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen.
5. The peptide of claim 4 , which comprises an amino acid sequence shown in one of SEQ ID NO: 6-46.
6. An epitope peptide consisting essentially of a peptide of claim 4 .
7. An inducer of CTL consisting essentially of a peptide of claim 4 as an active ingredient.
8. The peptide of claim 4 that binds to an HLA antigen in a HLA-A24 restricted manner and is recognized by CTLs when bound to an HLA-A24 antigen.
9. The peptide of claim 4 wherein the amino acid residue at position 2 of said fragment (ii) is tyrosine, phenylalanine, methionine, or tryptophan, and the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.
10. The peptide of claim 5 that consists of an amino acid sequence of one of SEQ ID NO: 6-46.
11. The peptide of claim 5 that consists of the amino acid sequence of SEQ ID NO: 6.
12. A method for producing an antigen-presenting cell comprising the step of bringing a cell having antigen-presenting ability into contact with a peptide which is 8-14 amino acids long and is
(i) a fragment of a protein, wherein the protein consists of the amino acid sequence shown in SEQ ID NO: 2; or
(ii) a fragment of a protein, wherein the protein consists of an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2
wherein the amino acid residue at position 2 of said fragment (ii) is tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine;
wherein said peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen.
13. The method of claim 12 in which the peptide binds to an HLA antigen in a HLA-A24 restricted manner and is recognized by CTLs when bound to an HLA-A24 antigen.
14. The method of claim 12 , wherein the peptide is:
(i) a fragment of a protein, wherein the protein consists of the amino acid sequence shown in SEQ ID NO: 2; or
(ii) a fragment of a protein, wherein the protein consists of an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2, and the amino acid residue at position 2 of said fragment (ii) is tyrosine, phenylalanine, methionine, or tryptophan, and the C terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.
15. A tumor marker consisting essentially of a peptide as set forth in claim 4 .
16. The tumor marker of claim 15 , which comprises at least 8 contiguous amino acids in the amino acid sequence shown in SEQ ID NO: 2.
17. The tumor marker of claim 15 , wherein the tumor is sarcoma or renal cancer.
18. A diagnostic agent for tumor consisting essentially of a tumor marker of claim 15 .